What is Duchenne Muscular Dystrophy?

Duchenne Muscular Dystrophy (DMD) is a genetic disorder that affects thousands of families worldwide. It primarily impacts boys, causing muscle degeneration and weakness over...

About our Mission

Many people in the world do not know what Duchenne muscular dystrophy is. Because only one in every 5,000 boys gets this disease. However, families and their surroundings whose children struggle with this disease have to live with the stress of this disease every day. We call them DMD Warriors.

DMDWarrior.com was established to raise awareness of this disease worldwide, facilitate access to treatments, and ensure that treatment costs are affordable.

dmd warrior dmdwarrior

What is our purpose?

One in every 5,000 children in the world is born with DMD, and many families only realize their child has the disease when they are 3-4 years old. FDA-approved treatments for DMD are too expensive for families to afford. Our goal is to reduce treatment costs and have the costs covered by the government.

Home

Ease of Access to Treatments

In many countries, DMD treatments are not available, and families incur huge costs for travel abroad.

Home

Reducing Treatment Costs

Treatments for DMD are very expensive, and it is nearly impossible for families to cover these costs themselves.

Home

Raising Awareness on Social Media

We do not want any child to die. If you also want to find a solution to this situation, follow us on social media.

News & Articles

ImmunoForge Receives FDA IND Approval for Phase 2 Clinical Trial of ‘Pemziviptadil’ for DMD Cardiomyopathy

A medication for DMD cardiomyopathy, pemziviptadil is used once a week and is based on ImmunForge's ELP Platform (Elastin Like Polypeptide Platform), a long-acting...

Sarepta Reiterated Total Net Product Revenue of $3.0 Billion in 2025

As children and families battling Duchenne Muscular Dystrophy wait for drug prices to drop, Sarepta has announced its earnings forecast for 2025. How much...

Wave Life Sciences Announces Plans for Exon 53 Skipping Study in 2025

Alpha-1 antitrypsin deficiency (AATD), Huntington's disease (HD), obesity, and Duchenne muscular dystrophy (DMD) are among the major unmet medical needs that the company seeks...

Edgewise Therapeutics Announces Plans for 2025

Edgewise Therapeutics has announced its 2025 plans for Duchenne muscular dystrophy. The company said in a statement that it will prioritize Sevasemten. Sevasemten is an...

Vamorolone (Agamree) Approved in Scotland

The medication vamorolone, also marketed under the brand name Agamree, has been approved by the Scottish Medicines Consortium (SMC) as a therapy option for...